Get started
VIRIDIAN THERAPEUTICS INC COM USD0.01VIRIDIAN THERAPEUTICS INC COM USD0.01VIRIDIAN THERAPEUTICS INC COM USD0.01

VIRIDIAN THERAPEUTICS INC COM USD0.01

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0K1R chart


Full chart

0K1R upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.96 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−4.2 USD
Net income (FY)
‪−237.73 M‬ USD
Revenue (FY)
‪314.00 K‬ USD
Shares float
‪67.61 M‬
Beta (1Y)
2.56

Employees


Employees (FY)
96
Change (1Y)
+10 +11.63%
Revenue / Employee (1Y)
‪3.27 K‬ USD
Net income / Employee (1Y)
‪−2.48 M‬ USD

About Viridian Therapeutics, Inc.


Sector
Health Technology
CEO
Stephen Frank Mahoney
Headquarters
Waltham
Website
viridiantherapeutics.com
Founded
2006
FIGI
BBG00JVRF6C1
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

0K1R news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0K1R is 23.2 USD — it has decreased by −6.43% in the past 24 hours. Watch VIRIDIAN THERAPEUTICS INC COM USD0.01 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange VIRIDIAN THERAPEUTICS INC COM USD0.01 stocks are traded under the ticker 0K1R.
0K1R stock has risen by 5.11% compared to the previous week, the month change is a 9.67% rise, over the last year VIRIDIAN THERAPEUTICS INC COM USD0.01 has showed a 58.17% increase.
We've gathered analysts' opinions on VIRIDIAN THERAPEUTICS INC COM USD0.01 future price: according to them, 0K1R price has a max estimate of 61.00 USD and a min estimate of 22.00 USD. Watch 0K1R chart and read a more detailed VIRIDIAN THERAPEUTICS INC COM USD0.01 stock forecast: see what analysts think of VIRIDIAN THERAPEUTICS INC COM USD0.01 and suggest that you do with its stocks.
0K1R reached its all-time high on Feb 5, 2018 with the price of 129.0 USD, and its all-time low was 9.2 USD and was reached on May 7, 2020. View more price dynamics on 0K1R chart.
See other stocks reaching their highest and lowest prices.
0K1R stock is 7.13% volatile and has beta coefficient of 2.56. Track VIRIDIAN THERAPEUTICS INC COM USD0.01 stock price on the chart and check out the list of the most volatile stocks — is VIRIDIAN THERAPEUTICS INC COM USD0.01 there?
Today VIRIDIAN THERAPEUTICS INC COM USD0.01 has the market capitalization of ‪1.71 B‬, it has increased by 10.38% over the last week.
Yes, you can track VIRIDIAN THERAPEUTICS INC COM USD0.01 financials in yearly and quarterly reports right on TradingView.
VIRIDIAN THERAPEUTICS INC COM USD0.01 is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
0K1R earnings for the last quarter are −1.15 USD per share, whereas the estimation was −1.06 USD resulting in a −8.77% surprise. The estimated earnings for the next quarter are −1.04 USD per share. See more details about VIRIDIAN THERAPEUTICS INC COM USD0.01 earnings.
VIRIDIAN THERAPEUTICS INC COM USD0.01 revenue for the last quarter amounts to ‪86.00 K‬ USD, despite the estimated figure of ‪84.92 K‬ USD. In the next quarter, revenue is expected to reach ‪55.17 K‬ USD.
0K1R net income for the last quarter is ‪−76.69 M‬ USD, while the quarter before that showed ‪−64.99 M‬ USD of net income which accounts for −18.00% change. Track more VIRIDIAN THERAPEUTICS INC COM USD0.01 financial stats to get the full picture.
No, 0K1R doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 14, 2024, the company has 96.00 employees. See our rating of the largest employees — is VIRIDIAN THERAPEUTICS INC COM USD0.01 on this list?
Like other stocks, 0K1R shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VIRIDIAN THERAPEUTICS INC COM USD0.01 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VIRIDIAN THERAPEUTICS INC COM USD0.01 technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VIRIDIAN THERAPEUTICS INC COM USD0.01 stock shows the buy signal. See more of VIRIDIAN THERAPEUTICS INC COM USD0.01 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.